Evergreen Wealth Solutions LLC Sells 1,298 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Evergreen Wealth Solutions LLC reduced its stake in Thermo Fisher Scientific by 62.5%, resulting in a holding worth $388,000 after selling 1,298 shares in Q1.
• Thermo Fisher reported earnings per share of $5.36 for the last quarter, exceeding analyst expectations, with revenue of $10.86 billion, up 2.9% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, with an ex-dividend date of September 15th, representing a 0.3% annualized yield.

Evergreen Wealth Solutions LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 62.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 780 shares of the medical research company's stock after selling 1,298 shares during the period. Evergreen Wealth Solutions LLC's holdings in Thermo Fisher Scientific were worth $388,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter valued at about $35,000. Finally, Navigoe LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HSBC reiterated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Robert W. Baird raised their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Stock Up 0.5%

Shares of TMO stock traded up $2.48 on Thursday, reaching $490.60. 1,407,667 shares of the company were exchanged, compared to its average volume of 2,011,074. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market cap of $185.25 billion, a price-to-earnings ratio of 28.37, a PEG ratio of 2.61 and a beta of 0.74. The company has a 50-day moving average of $448.63 and a 200-day moving average of $455.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.